Xponance Inc. Sells 375 Shares of Shockwave Medical, Inc. (NASDAQ:SWAV)

Xponance Inc. trimmed its position in Shockwave Medical, Inc. (NASDAQ:SWAV) by 4.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,901 shares of the company’s stock after selling 375 shares during the quarter. Xponance Inc.’s holdings in Shockwave Medical were worth $1,506,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Lindbrook Capital LLC raised its holdings in shares of Shockwave Medical by 64.8% in the 3rd quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock valued at $30,000 after purchasing an additional 59 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Shockwave Medical by 297.4% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company’s stock valued at $31,000 after purchasing an additional 116 shares during the period. Asset Management One Co. Ltd. bought a new stake in shares of Shockwave Medical in the 4th quarter valued at about $34,000. Operose Advisors LLC bought a new stake in shares of Shockwave Medical in the 3rd quarter valued at about $49,000. Finally, Venturi Wealth Management LLC bought a new stake in shares of Shockwave Medical in the 3rd quarter valued at about $82,000. 95.35% of the stock is owned by institutional investors.

Shockwave Medical Stock Performance

Shares of NASDAQ:SWAV opened at $328.54 on Wednesday. The company’s 50 day moving average price is $289.72 and its two-hundred day moving average price is $231.00. Shockwave Medical, Inc. has a 12-month low of $157.00 and a 12-month high of $331.58. The firm has a market cap of $12.29 billion, a PE ratio of 84.89, a PEG ratio of 2.44 and a beta of 0.92. The company has a quick ratio of 10.73, a current ratio of 11.76 and a debt-to-equity ratio of 1.09.

Shockwave Medical (NASDAQ:SWAV) last announced its earnings results on Thursday, February 15th. The company reported $1.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.24. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The firm had revenue of $202.98 million for the quarter, compared to analyst estimates of $199.43 million. During the same quarter in the prior year, the business posted $3.71 EPS. The business’s revenue was up 41.0% compared to the same quarter last year. Equities research analysts predict that Shockwave Medical, Inc. will post 4.94 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SWAV. Piper Sandler upped their target price on shares of Shockwave Medical from $290.00 to $360.00 and gave the company an “overweight” rating in a report on Tuesday, April 2nd. TheStreet raised shares of Shockwave Medical from a “c+” rating to a “b” rating in a report on Thursday, February 15th. Canaccord Genuity Group reiterated a “hold” rating and issued a $335.00 price target (up previously from $263.00) on shares of Shockwave Medical in a research note on Friday, April 5th. Wolfe Research reiterated a “peer perform” rating on shares of Shockwave Medical in a research note on Friday, April 5th. Finally, Wells Fargo & Company upped their price target on shares of Shockwave Medical from $200.00 to $210.00 and gave the company an “equal weight” rating in a research note on Friday, February 16th. Ten research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $309.11.

Insiders Place Their Bets

In other Shockwave Medical news, insider Isaac Zacharias sold 4,000 shares of the stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $224.69, for a total transaction of $898,760.00. Following the transaction, the insider now owns 63,920 shares in the company, valued at approximately $14,362,184.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Isaac Zacharias sold 4,000 shares of the stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $224.69, for a total transaction of $898,760.00. Following the sale, the insider now owns 63,920 shares in the company, valued at approximately $14,362,184.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Trinh Phung sold 1,287 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $232.18, for a total transaction of $298,815.66. Following the sale, the vice president now owns 32,933 shares in the company, valued at approximately $7,646,383.94. The disclosure for this sale can be found here. Insiders have sold a total of 93,813 shares of company stock worth $23,762,679 in the last quarter. Corporate insiders own 3.40% of the company’s stock.

Shockwave Medical Company Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.